A Study of Outcomes from the Use of Tranexamic Acid in Revision Total Joint Arthroplasty

Overview

About this study

The purpose of this study is to determine the best dosing plan and route of administration of tranexamic acid to minimize post-operative blood loss and transfusion requirements after a redo of a total knee replacement surgery.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Scheduled for revision THA or TKA defined as
- Femoral component exchange
- Acetabulum/tibial component exchange
- Both component exchange
- Explant of both components and placement of antibiotic cement spacer
- A second stage re-implantation procedure

Exclusion Criteria

Scheduled for a head and liner/poly exchange
Known allergy to TXA
Acquired disturbances of color vision
Refusal of blood products
Pre-operative use of anticoagulant therapy within five days before surgery
A history of arterial or venous thrombotic disease including
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Cerebrovascular Accident (CVA)
- Transient Ischemic Attack (TIA)
Pregnancy
Breastfeeding
Major co-morbidities
- Myocardial infarction or stent placement within one year
- Severe pulmonary disease
- Renal impairment
- Hepatic failure

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Matthew Abdel, M.D.	Closed for enrollment	Contact information: Matthew Abdel M.D. (507) 284-0069 Abdel.Matthew@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Abdel, M.D.

Closed for enrollment

Contact information:

Matthew Abdel M.D.

(507) 284-0069

Abdel.Matthew@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials